Anemia Not A “Deal Breaker” For Boceprevir – SPRINT-1 Study Investigator
This article was originally published in The Pink Sheet Daily
Executive Summary
Higher rate of anemia seen with HCV patients treated with boceprevir versus control is manageable, Schering maintains.